Tocilizumab in the Management of COVID-19: A Preliminary Report.

ABSTRACT:

Importance

Pneumonia due to COVID-19 can lead to respiratory failure and death due to the development of the acute respiratory distress syndrome. Tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, is being administered off-label to some patients with COVID-19, and although early small studies suggested a benefit, there are no conclusive data proving its usefulness.

Objective

To evaluate outcomes in hospitalized patients with COVID-19 with or without treatment with Tocilizumab.

Design, setting, participants

Retrospective study of 1938 patients with confirmed COVID-19 pneumonia admitted to hospitals within the Jefferson Health system in Philadelphia, Pennsylvania, between March 25, 2020 and June 17, 2020, of which 307 received Tocilizumab.

Expos

SUBMITTER: Li M 

PROVIDER: S-EPMC7649658 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature